Skip to content
Search

Latest Stories

NHS healthy living programme reduces Type 2 diabetes cases

NHS Diabetes Prevention Programme (NHS DPP) has helped to bring down the number of cases of Type 2 diabetes in England, a new research reveals. 

New data suggests the healthy living programme resulted in a seven per cent reduction in the number of new diagnoses of Type 2 diabetes in England between 2018 and 2019, with around 18,000 people saved the dangerous consequences of the condition.

Someone completing the nine month NHS scheme reduces their chances of getting the condition by more than a third (37 per cent), according to new University of Manchester research due to be presented at the annual Diabetes UK Professional Conference this week.


Prevention is a key part of the NHS Long Term Plan, which set out a major expansion of the Diabetes Prevention Programme.

Evidence has shown that the NHS spends around £10 billion a year on diabetes – around 10 per cent of its entire budget – and the NHS DPP is highly cost effective in the long-term.

Almost one million people have been referred to the programme since it was first launched in 2016, with participants who complete achieving an average weight loss of 3.3kg.

Since then, the NHS Long Term Plan expanded access so that up to 200,000 people a year will benefit as part of radical NHS action to tackle rising obesity rates and to prevent Type 2 diabetes.

The country’s top diabetes experts are expected to say that the programme will improve the health of hundreds of thousands of people.

Being diagnosed with Type 2 diabetes can have a devastating impact on people and their families – it is a leading cause of preventable sight loss in people of working age and is a major contributor to kidney failure, heart attack, stroke and many of the common types of cancer.

NHS National Clinical Director for Diabetes and Obesity, Professor Jonathan Valabhji, said: “The evidence is now clear – the NHS is preventing Type 2 diabetes and is helping thousands of people to lead healthier lives.

“Summer 2018 saw England become the first country to achieve universal coverage with such a programme. This latest evidence shows that the programme can have a major impact on peoples’ lives.”

Health and Social Care Secretary Sajid Javid said: “It is excellent to see the NHS Diabetes Prevention Programme, recently expanded as part of the NHS Long Term Plan, has helped 18,000 people avoid Type 2 diabetes – a serious and dangerous condition.

“It’s vital we focus on prevention and provide advice on healthy eating and exercise, as obesity can lead to a number of serious health conditions and is the second biggest cause of cancer in the UK.

“Programmes like this are helping people to live longer, healthier lives as part of our mission to level up the health of the nation and tackle disparities.”

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less